T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
Thomas Powles,Laurence Albiges,Axel Bex,Axel Bex,Viktor Grünwald,Camillo Porta,Giuseppe Procopio,Manuela Schmidinger,Cristina Suarez,G. De Velasco +9 more
Journal ArticleDOI
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Sergio J Azevedo,Delphine Borchiellini,Raymond S. McDermott,Jens Bedke,Satoshi Tamada,Shuyan (Sabrina) Wan,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +19 more
TL;DR: Pembro + axi significantly improved OS, PFS, and ORR vs sunitinib and had manageable toxicity a year after pembro - axi treatment, according to KEYNOTE-426.
Journal ArticleDOI
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Jens Bedke,Laurence Albiges,Umberto Capitanio,Rachel H. Giles,Milan Hora,Thomas B. Lam,Börje Ljungberg,Lorenzo Marconi,Tobias Klatte,Alessandro Volpe,Yasmin Abu-Ghanem,Saeed Dabestani,Sergio Fernández Pello,Fabian Hofmann,Teele Kuusk,Rana Tahbaz,Thomas Powles,Axel Bex,Axel Bex +18 more
TL;DR: The CheckMate-9ER trial as discussed by the authors showed an improved progression-free survival (PFS), overall survival (OS), and an objective response rate (ORR) benefit for the combination of lenvatinib plus pembrolizumab over sunitinib.
Journal ArticleDOI
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
Marie Auvray,Edouard Auclin,Philippe Barthélémy,Petri Bono,Pirkko Kellokumpu-Lehtinen,Marine Gross-Goupil,Guillettno De Velasco,Thomas Powles,Guillaume Mouillet,Yann-Alexandre Vano,Gwenaelle Gravis,Loic Mourey,Franck Priou,Frederic Rolland,Bernard Escudier,Laurence Albiges +15 more
TL;DR: In this article, the authors reported the first report of outcomes with TKI, after first-line nivolumab-ipilimumab failure, after 33 patients received subsequent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after nivolaumabipilumab failure.
Journal ArticleDOI
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Jens Bedke,Laurence Albiges,Umberto Capitanio,Rachel H. Giles,Milan Hora,Thomas B. Lam,Börje Ljungberg,Lorenzo Marconi,Tobias Klatte,Alessandro Volpe,Yasmin Abu-Ghanem,Saeed Dabestani,Sergio Fernández-Pello,Fabian Hofmann,Teele Kuusk,Rana Tahbaz,Thomas Powles,Axel Bex,Axel Bex,Axel Bex +19 more
TL;DR: The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab as mentioned in this paper.